[1. BREMBILLA NC, CHIZZOLINI C. T cell abnormalities in systemic sclerosis with a focus on Th17 cells. Eur Cytokine Netw. 2012; 23(4):128-39.10.1684/ecn.2013.032523360781]Search in Google Scholar
[2. ZHU J, PAUL WE. CD4 T cells: fates, functions, and faults. Blood. 2008; 112(5):1557-69.10.1182/blood-2008-05-078154251887218725574]Search in Google Scholar
[3. PAVLOVIC V, DIMIC A, MILENKOVIC S, KRTINIC D. Serum levels of IL-17, IL-4, and INFγ in Serbian patients with early rheumatoid arthritis. J Res Med Sci. 2014; 19(1):18-22.]Search in Google Scholar
[4. BĂLĂNESCU P, BĂLĂNESCU E, TĂNĂSESCU C, NICOLAU A, TĂNĂSESCU R, GRANCEA C, VAGU C, RUŢĂ S, BLEOŢU C. T helper 17 cell population in lupus erythematosus. Rom J Intern Med. 2010; 48(3):255-9.]Search in Google Scholar
[5. TANASESCU C, BALANESCU E, BALANESCU P, OLTEANU R, BADEA C, GRANCEA C, VAGU C, BLEOTU C, ARDELEANU C, GEORGESCU A. IL-17 in cutaneous lupus erythematosus. Eur J Intern Med. 2010; 21(3):202-7.10.1016/j.ejim.2010.03.00420493423]Search in Google Scholar
[6. CHIZZOLINI C, PAREL Y, SCHEJA A, DAYER JM. Polarized subsets of human T-helper cells induce distinct patterns of chemokine production by normal and systemic sclerosis dermal fibroblasts. Arthritis Res Ther. 2006; 8(1):R10.10.1186/ar1860152655216356198]Search in Google Scholar
[7. Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581-90.10.1002/art.17802305107378088]Search in Google Scholar
[8. GALIE N, HOEPER MM, HUMBERT M, TORBICKI A, VACHIERY JL, BARBERA JA, BEGHETTI]Search in Google Scholar
[9. M, CORRIS P, GAINE S, GIBBS JS, GOMEZ-SANCHEZ MA, JONDEAU G, KLEPETKO W, OPITZ C, PEACOCK A, RUBIN L, ZELLWEGER M, SIMONNEAU G, ESC Committee for Practice. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30:2493-2537.10.1093/eurheartj/ehp29719713419]Search in Google Scholar
[10. CLEMENTS P , LACHENBRUCH P, SEIBOLD J, WHITE B, WEINER S, MARTIN R, WEINSTEIN A, WEISMAN M, MAYES M, COLLIER D. Inter- and intraobserver variability of the total thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22:1281-5.]Search in Google Scholar
[11. AMANZI L, BRASCHI F, FIORI G, GALLUCCIO F, MINIATI I, GUIDUCCI S, CONFORTI ML, KALOUDI O, NACCI F, SACU O, CANDELIERI A, PIGNONE A, RASERO L, CONFORTI D,MATUCCI-CERINIC M. Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. Rheumatolgy (Oxford) 2010; 49:1374-82.10.1093/rheumatology/keq09720400463]Search in Google Scholar
[12. VALENTINI G, D’ANGELO S, DELLA ROSSA A, BENCIVELLI W, BOMBARDIERI S. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis. 2003; 62(9):904-5.10.1136/ard.62.9.904175465912922969]Search in Google Scholar
[13. OLEWICZ-GAWLIK A, DANCZAK-PAZDROWSKA A, KUZNAR-KAMINSKA B, GORNOWICZ-POROWSKA J, KATULSKA K, TRZYBULSKA D, BATURA-GABRYEL H, SILNY W, POPLAWSKI D, HRYCAJ P. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis. Int J Rheum Dis. 2014; 17(6):664-70.10.1111/1756-185X.1229024467649]Search in Google Scholar
[14. MURATA M, FUJIMOTO M, MATSUSHITA T, HAMAGUCHI Y, HASEGAWA M, TAKEHARA K, KOMURA K, SATO S. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? J Dermatol Sci. 2008; 50(3):240-2.10.1016/j.jdermsci.2008.01.00118329249]Search in Google Scholar
[15. ZHOU Y, HOU W, XU K, HAN D, JIANG C, MOU K, LI Y, MENG L, LU S. The elevated expression of Th17-related cytokines and receptors is associated with skin lesion severity in early systemic sclerosis. Hum Immunol. 2014 Dec 11. pii: S0198-8859(14)00508-4.]Search in Google Scholar
[16. GOURH P, ARNETT FC, ASSASSI S, TAN FK, HUANG M, DIEKMAN L, MAYES MD, REVEILLE JD, AGARWAL SK. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther. 2009; 11(5):R147.10.1186/ar2821278725919799786]Search in Google Scholar
[17. RADSTAKE TR, VAN BON L, BROEN J, HUSSIANI A, HESSELSTRAND R, WUTTGE DM, DENG Y, SIMMS R, LUBBERTS E, LAFYATIS R. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One. 2009 Jun 17; 4(6):e5903.10.1371/journal.pone.0005903269199119536281]Search in Google Scholar